More Emyria Ltd news
Emyria LtdASX: EMD

Emyria Gains Ethics Endorsement for Psilocybin Program

Oct 27, 2024 at 11:21 PM EDT · Issued by Emyria Ltd

Filed with ASX · Oct 27, 2024 at 11:21 PM EDT

On 6ix: 6ix.com/news/emyria-gains-ethics-endorsement-for-psilocybin-program

Emyria Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Emyria Ltd on 6ix

Story so far

  • Emyria to Develop Psilocybin Therapy Care ModelApr 18, 2023

Earlier from Emyria

  • Emyria Shares Interim Success in PTSD Treatment ProgramSep 2, 2024
  • Appendix 4E & Annual Report for the Year Ended 30 June 2024Aug 30, 2024
  • June 2024 Quarterly Activities Report and Appendix 4CJul 29, 2024
  • Emyria, UWA Secure $499K Grant for MDMA Analogue ProgramJun 30, 2024
  • Empax Centre Selected As Key Site In Global PTSD StudyJun 19, 2024

Later from Emyria

  • September 2024 Quarterly Activities Report and Appendix 4COct 29, 2024
  • Emyria & UWA Partner to License Novel Serotonin TherapiesOct 30, 2024
  • Response to ASX Price QueryNov 12, 2024
  • Emyria Secures $2.525M in Strongly Supported PlacementNov 26, 2024
  • Leadership UpdatesJan 21, 2025
All Emyria news releases↗

Follow Emyria into a list and get an email when it puts out news.

Follow Emyria
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer